1	Investigation of pharmaceuticals in processed animal by-products by
2	liquid chromatography coupled to high-resolution mass spectrometry.
3	
4	Jaime Nácher-Mestre, ^{a,b§} María Ibáñez, ^a Roque Serrano, ^a Clara Boix, ^a
5	Lubertus Bijlsma, ^a Bjørn Tore Lunestad, ^c Rita Hannisdal, ^c Martin Alm, ^d
6	Félix Hernández, ^a and Marc H.G. Berntssen ^{c*}
7	
8	^a Research Institute for Pesticides and Water (IUPA). Avda. Sos Baynat, s/n. University
9	Jaume I, 12071 Castellón, Spain.
10	^b Institute of Aquaculture of Torre la Sal (IATS, CSIC), 12595 Ribera de Cabanes,
11	Castellón, Spain.
12	^c National Institute of Nutrition and Seafood Research, PO Box 2029 Nordnes, N-5817
13	Bergen, Norway.
14	^d European Fat Processors and Renderers Association (EFPRA). Boulevard Baudouin
15	18, 4th floor, BE - 1000 Brussels.
16	
17	
18	
19	
20	
21	

22 Abstract

23 There is an on-going trend for developing more sustainable salmon feed in which 24 traditionally applied marine feed ingredients are replaced with alternatives. Processed 25 animal products (PAPs) have been re-authorized as novel high quality protein 26 ingredients in 2013. These PAPs may harbor undesirable substances such as pharmaceuticals and metabolites which are not previously associated with salmon 27 28 farming, but might cause a potential risk for feed and food safety. To control these 29 contaminants, an analytical strategy based on a generic extraction followed by ultra-30 high performance liquid chromatography coupled to high resolution mass spectrometry 31 (UHPLC-HRMS) using quadrupole time-of-flight mass analyzer (QTOF MS) was 32 applied for wide scope screening. Quality control samples, consisting of PAP 33 commodities spiked at 0.02, 0.1 and 0.2 mg/kg with 150 analytes, were injected in every 34 sample batch to verify the overall method performance. The methodology was applied 35 to 19 commercially available PAP samples from six different types of matrices from the 36 EU animal rendering industry. This strategy allows assessing possible emergent risk 37 exposition of the salmon farming industry to 1005 undesirables, including 38 pharmaceuticals, several dyes and relevant metabolites. 39

40 **KEYWORDS:** aquaculture, processed animal products, salmon, liquid

41 chromatography, screening, undesirables, pharmaceuticals, dyes, quadrupole time-of-42 flight.

43 * Corresponding author. Tel. (+47) 99487708; e-mail address: Marc.Berntssen@nifes.no

44 [§] Current press and address: Nutrigenomics and Fish Growth Endocrinology Group, Institute of

45 Aquaculture Torre la Sal, IATS-CSIC, Ribera de Cabanes, Castellón, Spain

46 INTRODUCTION

47 Estimated global production of farmed salmon (including Salmo salar, Oncorhynchus 48 kisutch, O. tshawytscha) in 2010 was approximately 1.8 million metric tonnes with 49 expected production of around 2.9 million metric tonnes in 2020 (Tacon et al., 2008). 50 Furthermore, consumption of all species of farmed fish is expected to exceed that of 51 feral fish (FAO, 2014). Traditional commercial feed for farmed salmon and rainbow 52 trout are based on marine feed ingredients extracted from pelagic fish stocks. Concern 53 of pressure on feral fish stocks and limited fish meal and fish oil availability to supply a 54 rapidly growing aquaculture industry has led to the development of aquafeeds in which 55 marine resources are replaced with alternative feed ingredients to develop more 56 sustainable marine aquafeeds (Tacon et al., 2008; Torrisen et al., 2011; Waago et al., 57 2013). On a global basis, processed animal products (PAP) from the rendering industry 58 constitute one of the largest sources of high quality animal protein available for animal 59 feed production (Toldra et al., 2012). The use of PAPs such as feather meal, poultry by-60 product meal, pork meat and bone meal, and poultry and pork blood meal have been 61 shown to be relevant nutritional replacements of fish meal for many cultured fish 62 species including salmonids (Brandsen et al., 2001; Rosenlund et al., 2001; Yanik et al., 63 2003; Rahnema et al., 2007; Wilson et al., 2007; Friesen et al., 2008; Poppi et al., 2011; 64 Burr et al., 2012). However, following the peak outbreaks of transmissible spongiform 65 encephalopathies (TSE) in the UK in the early 1990's, the use of PAPs in all animal 66 feed was banned in the European Union (EU) in 2001 (EC, 2001; EC, 2003a). 67 Following a bovine spongiform encephalopathies (BSE) risk assessment by the 68 European Food Safety Authorities (EFSA) (EFSA, 2011), the EU set out a working plan 69 for the re-authorization of the use of non-ruminant PAPs in animal feed, initially for 70 aquafeeds in 2013 (EC, 2013a).

71 In EU, the use of veterinary drugs is regulated according to EU legislation. Permitted 72 residue levels of pharmaceutical substances (EC, 2009a) and mandatory monitoring 73 activity (EC, 1996) have been established for all food producing animals. These 74 regulations affect the legal addition of pharmaceuticals to animal feed, including the 75 prohibition of substances in feeds that have hormonal or thyreostatic action as well as β -76 agonist (EC, 2003b). In addition, the supplementation of coccidiostats or histomonostats 77 as feed additive causing unavoidable carry-over in non-target feed is regulated in the 78 EU (EC, 2009b). In Norway, the use of pharmaceuticals in Atlantic salmon farming is 79 under strict control and all sales of pharmaceuticals in animal farming have to be 80 reported to the Norwegian Food Safety Authority. Open and reliable statistics on the 81 consumption of therapeutic agents in aquaculture is only available from some nations. 82 As an example, the registered use of pharmaceuticals in Norwegian aquaculture in 2014 83 included the antimicrobials florfenicol and oxolinic acid, the anti-parasitic agents 84 azametifos, cypermetrin, deltametrin, diflubenzuron, teflubenzuron, emamectin, 85 praziquantel and hydrogen peroxide, as well as the anaesthetic agents benzocaine, 86 metacaine and isoeugenol (available at http://www.fhi.no/artikler/?id=114175) (Grave 87 et al., 2008).

88 The use of PAPs in salmon feed can potentially introduce new chemical undesirables 89 that have not been previously associated with farmed Atlantic salmon. Of special 90 interest are pharmaceuticals such as antibacterials, which are used in all sectors of 91 farming, including poultry and swine production (Toldra et al., 2012). Other pharmaceutical agents used in terrestrial farmed animals include antiparasitic agents 92 93 such as coccidiostats, which are added to poultry feed to cope with protozoa as well as 94 enhancing animal growth (Ruff, 1999; Chapman, 2014). It should be kept in mind that 95 the number of pharmaceuticals used in terrestrial animals is more diverse than those 96 used for fish, and that there are substantial differences in the prescribing patterns of

97 veterinary agents between countries and regions (EMA, 2011). Earlier screening studies 98 on feather meal from the USA (10 samples) and China (2 samples) for 59 99 pharmaceuticals, showed the presence of six classes of antimicrobials including 100 fluoroquinolones, tetracyclines, folic acid antagonists, and streptogramins (Love et al., 101 2012). Two of the main antibacterials were enrofloxacin and ciprofloxacin, and studies 102 in EU also showed the occurrence of these substances in poultry and pork PAPs 103 (Berntssen et al., 2014). In addition to potentially direct adverse health effects of 104 pharmaceutical residues in food and non-compliance with food legislation, concern has 105 been raised for the development of resistant pathogenic microorganisms when exposed 106 to low non-clinical residue levels (Reig et al., 2009; Blazquez et al., 2012; Gillings et 107 al., 2013).

108 The list of prohibited and allowed antibiotics in the EU includes many substances which 109 may co-occur in samples of animal origin. This requires the use of comprehensive 110 screening methods for detection of these substances (Bohn et al., 2013; Nácher-Mestre, 111 et al., 2013; Masiá et al., 2014; Turnipseed et al., 2014; Boix et al., 2014). Therefore, generic sample treatment is advisable to cover as many compounds as possible during 112 113 the experimental process. High resolution mass spectrometry (HRMS) allows the 114 acquisition of full-spectrum accurate-mass data using analyzers such as quadrupole 115 time-of-flight (QTOF). The coupling of liquid chromatography (LC) with QTOF MS is 116 nowadays one of the most efficient analytical tools to face the investigation of large 117 number of medium-high polar organic contaminants and residues in food-safety and 118 related fields (Ibañez et al., 2012). The present study reports a wide-scope qualitative 119 screening approach for 1005 permitted and prohibited pharmaceutical residues (also 120 including metabolites) and dyes in commercially available EU produced PAPs with 121 potential use in aquafeed.

122 MATERIAL AND METHODS

123 Reagents and chemicals. 150 reference standards were purchased from Acros Organics

124 (Geel, Belgium), Aventis Pharma (Madrid, Spain), Bayer Hispania (Barcelona, Spain),

125 Cerilliant (Round Rock, TX, USA), Fluka (Buchs, Switzerland), Dr. Ehrenstorfer

126 (Augsburg, Germany), Fort Dodge Veterinaria (Gerona, Spain), National Measurement

127 Institute (Pymble, Australia), Riedel-de Haën (Seelze, Germany), Sigma Aldrich (St

128 Louis, MO, USA), Vetoquinol Industrial (Madrid, Spain), and Witega (Berlin,

129 Germany). All reference materials had purities higher than 98% (w/w), except for

130 marbofloxacin and pefloxacin, which had purities higher than 93%.

131 HPLC-grade water was obtained from a MilliQ water purification system (Millipore

132 Ltd., Bedford, MA, USA). HPLC-grade methanol, HPLC-supragradient acetonitrile and

133 acetone for residue analysis were purchased from Scharlab (Barcelona, Spain). Formic

134 acid (HCOOH, content > 98%), ammonium acetate (NH₄Ac, reagent grade) and sodium

135 hydroxide (NaOH, reagent grade) were supplied by Scharlab. Leucine enkephalin was

136 purchased from Sigma Aldrich.

137

138 Samples. Commercially available PAPs were studied in this work. A total of 19 139 available non-ruminant PAPs from 6 different types of matrices were provided by the 140 European Fat Processors and Renderers Association (EFPRA). The samples had been 141 produced in different rendering factories. All PAPs were produced according to EU 142 regulation for PAPs intended for use as feed ingredients (EC, 2001; EC, 2009c). All 143 PAPs were "category 3 products" which are fit for human consumption at the point of 144 slaughter as defined by EU-legislation (EC, 2009c). The PAPs obtained included six 145 different matrices: poultry blood meal (n=4), poultry meal (n=4), feather meal (n=3), 146 pork blood meal (n=3), pork meal (n=3) and pork greaves (n=2). Samples were stored at -20°C until analysis (within one week). The PAPs included are all produced in central
Europe and are firmly considered to be used for future aquafeeds after the lift of the ban
on these products in the EU food supply chain.

150

151 Instrumentation. A Waters Acquity UHPLC system (Waters, Milford, MA, USA) was 152 coupled to a quadrupole-orthogonal acceleration-TOF mass spectrometer (XEVO G2 153 QTOF, Waters Micromass, Manchester, UK), with a Z-spray-ESI interface, operating in both positive and negative ionization modes. An Acquity UHPLC BEH C18 1.7 µm 154 155 particle size analytical column 2.1×100 mm (Waters) at a flow rate of 300 µL/min was 156 employed for chromatographic separation. Mobile phase consisted of water/methanol 157 gradient both with 0.01% HCOOH and 0.1mM NH₄Ac. The percentage of organic 158 modifier (B) was changed linearly as follows: 0 min, 10 %; 14 min, 90 %; 16 min, 90 159 %; 16.01 min, 10 %; 18 min, 10 %. The column temperature was set at 40 °C. Hybrid 160 TOF MS resolution was approximately 20,000 at full width half maximum (FWHM), at 161 m/z 556. MS data were acquired in the m/z range of 50-1000. A capillary voltage of 0.7 162 kV in positive mode and 2.5 kV in negative mode were used with a cone voltage of 20 163 V. Collision gas was argon 99.995% (Praxair, Valencia, Spain). The interface 164 temperature was set to 650 °C and the source temperature at 130 °C. For MS^E experiments (also known as all-ion fragmentation or broadband collision-165 166 induced dissociation by other manufacturers), two sequential acquisition functions were 167 created: in the low energy function (LE), a collision energy of 4 eV is selected, 168 obtaining a conventional full spectrum where intact (de)protonated molecules/adducts 169 are commonly observed; in the high energy function (HE), a linear collision energy 170 ramp from 15 to 40 eV is applied in order to induce ion fragmentation. In this way, 171 fragmentation information is obtained in advance for all compounds in a single run

without the need for re-injecting the sample in MS/MS mode. Scan time of 0.4 s wasselected.

174 Calibrations were conducted daily from m/z 50 to 1000 with a 1:1 mixture of 0.05M NaOH:5% HCOOH diluted (1:25) with acetonitrile:water (80:20), at a flow rate of 20 175 176 μ L/min. For automated accurate mass measurement (i.e. real-time calibration), a 177 solution of leucine enkephalin (10 mg/L) in acetonitrile:water (50:50) at 0.1% HCOOH 178 was used as lock mass and pumped at 30 μ L/min through the lock-spray needle. The 179 (de)protonated molecule of leucine enkephalin at m/z 556.2771 in positive mode and 180 m/z 554.2615 in negative mode was used for recalibrating the mass axis and ensuring a 181 robust accurate mass measurement along time. MS data were acquired in centroid mode 182 and processed by the ChromaLynx XS application manager (within MassLynx v 4.1; 183 Waters Corporation).

184

185 **Recommended analytical procedure.** A generic sample procedure has been expanded 186 to PAPs following a screening strategy previously validated for aquaculture matrices 187 (Nácher-Mestre et al., 2013) and feed samples (Boix et al., 2014). Briefly, PAPs were 188 thawed at room temperature and 2.5 g of sample (dry weight) was accurately weighed 189 (precision 0.01g) in centrifuge tubes (50 mL) and homogenized in a Vortex with 10 mL 190 acetonitrile:water (80:20, v/v) 0.1% HCOOH. After shaking the samples for one hour, 191 the tubes were placed in an ultrasonic bath during 15 minutes followed by 192 centrifugation at 4500 rpm for 10 min. Then, an aliquot of 1 mL of supernatant extract 193 was transferred to an eppendorf vial, diluted with 1 mL of HPLC-grade water and stored 194 in a freezer (minimum 2 hours) to precipitate proteins. After that, the extract was again 195 centrifuged at 12000 rpm for 10 min and supernatant was transferred to another vial.

Finally, 20 µL of the extract (final composition acetronitrile:water (40:60, v/v) 0.05%
HCOOH) was injected into the UHPLC-QTOF MS.

198

199 Quality assurance. Sample batches consisted of 20-30 vials, including 4 standards 200 (only for qualitative purposes) and quality control samples (QCs). The reliability of the 201 qualitative screening was assessed by the analysis of three QCs per matrix at different 202 concentration levels. To this aim, six different PAPs (each representing the matrices 203 studied, see samples section) were spiked with 150 pharmaceutical agents (including 4 204 dyes, see Sup. info for more details) at three different concentration levels (0.02, 0.1 and 205 0.2 mg/kg), and analyzed together with their respective "blanks". Additionally, two 206 method blanks were analyzed to assure that no laboratory contamination was introduced 207 in the procedure. This approach was carried out following the spirit of European 208 guidelines (EC, 2002; EC, 2013b).

209

210 **RESULTS AND DISCUSSION**

UHPLC-QTOF MS screening. Satisfactory chromatographic peaks, i.e. at least 10 data points per peak, for all 150 compounds were obtained. Formic acid (0.01 %) was added to both water and methanol mobile phase solvents, favoring the formation of the protonated molecule in positive ionization mode. The addition of ammonium acetate in the mobile phase allowed improving peak shapes (Gracia-Lor et al., 2010). In general, the best results in terms of sensitivity were obtained under positive ionization mode selecting the protonated molecule as the main diagnostic ion.

218 With the previous chromatographic conditions, the screening was applied on the basis

of a compound database that is being continuously updated (Nácher-Mestre et al., 2013;

220 Boix et al., 2014). At this stage, new pharmaceuticals were included into our previous

221 lists in order to investigate their possible presence in PAP matrices of interest for 222 salmon aquafeed. Individual standard solutions were injected to study MS 223 fragmentation of each target analyte, achieving a final list of 150 analytes, which were 224 also used for quality control of the qualitative screening. The selected compounds were 225 representative from different families with quite different chemical-physical 226 characteristics and were used to test the applicability of the screening. Briefly, 75% of 227 the 150 compounds used in QC analysis were detected in all matrices at 0.2 mg/kg and 228 65% at 0.1 mg/kg, decreasing down to 30% at the lowest spiking level of 0.02 mg/kg. 229 Many of the compounds that could not be detected in all spiked samples were however 230 detected in some of them, sometimes even in 5 out of 6 samples. In those cases, we did 231 not consider the screening as satisfactory at the concentration level tested, as the 232 requirement was to have 100% of positive samples detected. This was mostly due to the 233 high variability in matrix composition between the samples used for preparing QCs. 234 In addition to these 150 compounds, up to 855 compounds were searched in the samples making a total target list of 1005 compounds. The compound database used can be 235 236 found in supporting information, including Retention time (Rt) (when the reference 237 standard was available) and the elemental composition used for characterization. With 238 so high number of compounds, it might be possible that some of them co-elute (for 239 example, sulfaguinoxaline and sulfathiazole at 6.51 min). Under this situation, UHPLC 240 was valuable for choosing almost co-eluting fragment ions that would correspond to the 241 same precursor avoiding spectrum interferences that would complicate the identification 242 process. Not only the retention time but also the chromatographic peak shape were 243 taken into account to match each fragment ion to the correct "precursor ion". Anyway, 244 as a hybrid QTOF was used, additional MS/MS experiments could be performed, if 245 necessary, in analysis of real-world samples for confirmation of positives in case of

246 doubt. For adequate retention time comparison, LC conditions used (LC column, mobile247 phase and gradient) should be the same than those used when creating the database.

248 **Detection and identification criteria.** Figure 1 illustrates the criteria used in this work. 249 The parameters considered for a satisfactory detection and identification were Rt, mass 250 accuracy (i.e. mass errors), q_i/Q ratios (Q: the most abundant ion –commonly the 251 (de)protonated molecule; qi: fragment ion -or occasionally an adduct) and the isotopic 252 distribution pattern (especially for Cl and Br) (Hernández et al., 2015). Requirements 253 and interpretation of results were in agreement with Commission Decision 254 2002/657/EC, which applies to the monitoring of certain substances and residues 255 thereof in live animals and animal products (EC, 2002). In addition, SANCO guideline 256 for pesticide residue analysis in food was of help in terms of mass accuracy 257 requirements (EC, 2013b). The key parameters when testing the screening were 258 detection and identification of the compound in the sample at the concentration levels 259 tested. Neither recovery nor precision were calculated (contrarily to quantitative 260 methods), which is in the line of the guidelines used nowadays in food safety or doping 261 control analysis (EC, 2002; EC, 2013b; FDA, 2015; WADA 2010). Several situations 262 were considered in the screening depending on the reference standard availability 263 (Figure 1):

264 1) Reference standard available:

Detection was considered satisfactory when the most abundant ion (Q),
 commonly the (de)protonated molecule, was found at the expected Rt (deviation
 accepted ± 2.5% in comparison with the reference standard) (EC, 2002) and
 mass error was below 5 ppm (named as "d1") (EC, 2013b). Another likely

situation for detection was to find two representative m/z ions (i.e. the most

abundant ion (Q) and/or minor fragment/adduct ions (q)) for the target

compound at the expected Rt, but with mass errors between 5-20 ppm (named as
"d2"). The latter situation seemed to occur when the signal intensity was low
(favored at low analyte concentrations). In that case, an additional effort is
recommended to investigate more accurate-mass ions and/or repeat sample
injection, if possible.

276- Identification was based on the presence of at least two representative m/z ions277(Q, q) at the expected Rt ($\pm 2.5\%$, in comparison with the reference standard)278with mass errors below 5 ppm. Additionally, q/Q ratios should fit with those for279reference standards within tolerance limits admitted which range from 20% to28050 % depending on the q/Q ratio (<0.1:50%, 0.1-0.2:30%, 0.2-0.5:25% and,</td>281>0.5%:20%) (EC, 2002). Identification under these conditions was highly282reliable and it was considered as the ideal situation.

In both cases, the characteristic isotopic pattern (e.g. when ions as Cl or Br are present) should be observed.

285 2) Reference standard not available:

286 Tentative identification could be made when an expected ion with mass error below 287 5 ppm was observed, together with its characteristic isotopic pattern. Subsequently, 288 the fragment ions (q_i) (or characteristic isotopic ions) were evaluated. For this 289 purpose, different possibilities are available, such as comparing experimental 290 MS(/MS) spectra or the main fragment ions with those reported in the literature 291 (massbank, METLIN public library), or justifying the accurate-mass fragments 292 taking into account the structure of the molecule. So, tentative identification 293 required the presence of one or more fragment ions (q) compatible with the 294 chemical structure of the candidate (mass error < 5 ppm) and/or in agreement with 295 previous data reported in literature. Retention time prediction may also help in this

process (focusing research only on "predicted" peaks) (Bade et al., 2015). Although
tentative identification was strongly supported by accurate-mass data obtained, the
confirmation of the identity requires the injection of the reference standard.

299

300 Screening of PAP samples. The HRMS screening developed allows research 301 laboratories to apply a cost-effective strategy to extend their analytical scope to analytes 302 which might potentially be present in the samples even without the need of having all 303 reference standards (EC, 2013b). In this way, laboratories do not need to acquire all 304 reference standards before analysis, with the subsequent problems of availability (e.g. 305 metabolites and transformation products), costs and expiry dates. Accurate-mass full-306 spectrum acquisition capabilities of the TOF analyzer made feasible the investigation of 307 many undesirables in a single run injection. In absence of standards, the only 308 information available for data processing was the elemental composition (i.e. accurate-309 mass), but a tentative identification could be made if sufficient information was 310 obtained from analyses (see Figure 1). 311 With the objective to support the reliability of the screening procedure, figure 2 shows a 312 sample matrix (poultry meal) fortified with the antibiotic enrofloxacin. The standard of 313 this fluoroquinolone was previously injected, selecting two representative m/z ions, the 314 protonated molecule (Q) and one fragment ion (q) for the reliable identification (Figure 315 2-A). Figure 2-B shows the same m/z ions of a quality control sample at 0.1 mg/kg 316 supporting the suitability of the method at this concentration level (mass deviations and 317 q/Q were satisfactory). Finally, figure 2-C shows the identification of enrofloxacin in a 318 PAP sample. The presence of two m/z ions, measured at the expected retention time, with acceptable mass deviations and appropriate q/Q ratios, allowed to identify this 319 320 compound in that sample.

321 After applying the described screening strategy to 19 PAP samples, pharmaceutic 322 agents like monensin, flumequine, enrofloxacin, trimethoprim, tylosin A, 323 acetaminophen, salicylic acid, oxyphenylbutazone, and the dye leucocrystal violet 324 (metabolite of the crystal violet dye) were found (Table 1). 325 Monensin is an antibiotic also allowed as a coccidiostat feed additive with an 326 established maximum residue level (MRL is 1.25 mg/kg for feed materials) for 327 unintended cross-contamination to non-target animal feed (EC, 2009b). The antibiotics 328 flumequine, enrofloxacin, trimethoprim and tylosin A, are authorized pharmaceutical 329 products in the EU with set MRLs in fish products (EC, 2009a); however in Norway, 330 these pharmaceuticals have not been registered for aquaculture use for the last decade 331 (Grave et al., 2008). The analgesics acetaminophen (paracetamol) is allowed to use for 332 porcine, and salicylic acid is allowed to use for all food producing species except fin 333 fish. Oxyphenylbutazone is a non-steroidal anti-inflammatory drug (NSAID) which is 334 not listed as an authorized drug in the EC directive (EC, 2009b), and crystal violet is a 335 potential carcinogenic pharmaceutical triphenylmethane dye, illegal for use in food-336 producing animals in the EU (Serratosa et al., 2006). As opposed to the other 337 pharmaceuticals identified in the study, crystal violet is not allowed to be used in the 338 food production chain in the EU, and its potential source in PAPs is hence unclear. 339 However, crystal violet can be unintendedly introduced as marker dye to identify treated 340 farm animals. Outside the EU it is used as an antimicrobial agent to prevent the fungal 341 growth in animal feeds (Mani and Bharagava, 2016). 342 Figure 3 illustrates the identification of trimethoprim, flumequine and salicylic acid in 343 different PAP samples analyzed. Figure 3-A corresponds to trimethoprim found in 344 feather meal. Three representative m/z ions with mass deviations below 5 ppm were 345 observed together with acceptable q/Q ratios. Figure 3-B corresponds to flumequine,

346 also in feather meal, where two representative m/z ions were present with acceptable

347 mass errors and q/Q deviations (<25%). However, in this sample the fragment with m/z348 174.036 was not clearly observed. Finally, figure 3-C shows the identification of 349 salicylic acid in pork blood meal with again two representative m/z ions. The fact that 350 salicylic acid is a small molecule made that few fragments were available under the 351 experimental conditions applied. Both salicylic acid and acetylsalicylic acid are allowed 352 to be used in all food producing species except fin fish or use in animals from which 353 milk or eggs are produced for human consumption (EC, 2009a). The presence of this 354 analgesic might be related to the previous administration of acetylsalicylic acid in 355 animals, a known pain reliever, anti-inflammatory and antipyretic drug, producing 356 salicylic acid as a metabolite. Besides this, salicylic acid is also used as an agent against 357 fungal diseases in the skin of animals. However, since salicylic acid is known to be 358 found in several plants (Venema et al., 1996; Scotter et al., 2007), it could also be 359 present in feed ingredients for livestock and subsequently in by-products from livestock 360 animals. Furthermore, salicylic acid has been previously detected in man and animals 361 not medicated by salicylic acid derived therapeutics (Paterson et al., 2008). 362 Figure 4 illustrates two situations where the compounds detected in poultry blood meal 363 could not be fully identified. Figure 4-A shows two m/z ions for leucocrystal violet but 364 the m/z 239.1548 (q₁), corresponding to the fragment C₁₆H₁₈N₂, presented mass error 365 higher than 5 ppm and further study of other fragment ions failed. In addition, q_1/Q ratio 366 was higher than 20% (tolerance permitted for q/Q>0.5). Therefore, the identification 367 criteria were not met, and we considered this compound as detected but not identified 368 (d2 following criteria from Figure 1). A similar situation occurred with tylosin A 369 (Figure 4-B) for which three representative ions were found at the same Rt, in 370 agreement with the standard. However, it was reported only as detected (d2) because all 371 the ions presented high mass errors. This might be due to the high mass of this 372 compound, very close to the higher end of the mass axis calibration range. Although it

373 seemed that both compounds were present in the sample, they could not be identified in
374 a reliable way; therefore, further analysis should be carried out for confirmation of their
375 identity.

376 The data processed also revealed the suspicious presence of ciprofloxacin and dyes such 377 as crystal violet, malachite green and leucomalachite green in PAPs, but with such a 378 low intensity that a second target analysis with a higher sensitivity technique (e.g. LC-379 MS/MS with triple quadrupole) would be necessary. Thus, further work is required for 380 those compounds identified (or tentatively identified) by this qualitative screening in 381 order to confirm their presence and determine the concentration levels in the samples. 382 This could be ideally made by LC-MS/MS using target quantitative methods developed 383 for the compounds revealed by QTOF MS screening.

384 In conclusion, the LC-HRMS screening methodology developed in this work has

385 revealed the presence of some pharmaceutical agents and marker dyes in re-authorized

386 PAPs that might be introduced in novel salmon feed. The qualitative validation was

387 performed for 150 compounds, and it was satisfactory for a notable number of analytes.

388 Most of compounds that could not be detected in 100% of the spiked samples were

389 however detected in several of them (in some cases up to 5 out of 6 samples),

390 illustrating that the screening was satisfactory in nearly all matrices tested. The lack of

391 sensitivity seemed to be the main reason for the non-detections, a drawback that can be

392 solved with the last-generation HRMS instruments that offer much better sensitivity that

393 the QTOF MS used in the present work.

394 Although the screening was tested for a limited number of compounds, it might be

assumed to be applicable to the wide majority of the remaining compounds included in

the database, as the contaminants used for validation covered a broad range of

397 physicochemical properties. Obviously, the only way to ensure a completely reliable

398 screening would be performing a full validation for all compounds, a task that seems 399 extremely complicated when dealing with hundreds of analytes. Yet, in the present 400 work, one can ensure the positive findings owing to the power of accurate-mass full 401 spectrum acquisitions in HRMS, reaching reliable tentative identifications even when 402 the standard is not available. Nevertheless, these tentative identified compounds should 403 be confirmed by acquiring the reference standard in a subsequent step. A major 404 advantage of this approach is that laboratories do not need to purchase hundreds of 405 standards for compounds that in many cases will never be found in the samples. In fact, 406 standards only need to be purchased in a subsequent step on the basis of the tentative 407 identifications in the samples. However, this type of screening has the drawback that 408 false negative results may occur for the compounds that have not been subjected to 409 validation. The proposed strategy is of interest for food safety and public health control 410 authorities as the presence of unintended background levels of illegal pharmaceutical 411 dyes, unreported antibiotics, or unauthorized anti-inflammatory agents in salmon feed 412 ingredients might give cause to legal actions. The approach presented in this paper can 413 be considered as a useful risk assessment tool for feed industry in order to widen the 414 knowledge on novel ingredients and also traditional ingredients under use. Also of 415 interest is the fact that accurate-mass full-spectrum acquisition allows widening the 416 search to other compounds not included in this work. This can be done at any time in 417 the future by retrospective evaluation of data obtained without additional analysis. In 418 the near future, routine monitoring and quantification of the compounds detected will be 419 carried out due to the potential implications in food safety.

420

421 ACKNOWLEDGMENTS

422 The authors acknowledge the financial support of the SAFETY-PAP project from the 423 Research Council Research and Development (227387), National Institute of Nutrition 424 and Seafood Research (NIFES, Norway). The authors also acknowledge the financial 425 support from Generalitat Valenciana to the research group of the University Jaume I (Group of Excellence Prometeo 2009/054, Prometeo II 2014/023; Collaborative 426 427 Research on Environment and Food Safety ISIC/2012/016). This work has been partly 428 developed in the framework of the Research Unit of Marine Ecotoxicology (IATS 429 (CSIC)-IUPA (UJI)). The authors wish to thank Richard Bade for skillful technical 430 assistance regarding retention time prediction.

431

432 SUPPORTING INFORMATION

433 The compound database used in this work can be found in supporting information,

434 including Retention time (Rt) (when the reference standard was available) and the

435 molecular composition used for characterization.

436

437 **REFERENCES**

438 Bade, R., Bijlsma, L., Miller, T.H., Barron, L.P., Sancho, J.V., Hernández, F. 2015.

439 Suspect screening of large numbers of emerging contaminants in environmental

440 waters using artificial neural networks for chromatographic retention time prediction

441 and high resolution mass spectrometry data analysis. Sci. Tot. Environ. 538, 934-

442 941.

443 Berntssen, M.H.G., Valdersnes, S., Lunestad, B.T., Hatlen, B., Alm, M., Waagbo, R.,

444 Buttle, L. 2014. Residue levels of enrofloxacin and ciprofloxacin in processed animal

445 by-products used in Atlantic salmon feeds and their long-term carry-over to the

edible part of the fish. Aquac. Nutr. 20, 712-721.

447	Blazquez, J.,	Couce, A.,	Rodriguez-	Beltran, J.,	Rodriguez-R	oias. A.	. 2012.
						- J ···· - J ···	

- 448 Antimicrobials as promoters of genetic variation. Curr. Opin. Microbiol. 15, 561-449 569.
- 450 Bohn, T., Pellet, T., Boscher, A., Hoffmann, L. 2013. Developing a microbiological
- 451 growth inhibition screening assay for the detection of 27 veterinary drugs from 13
- 452 different classes in animal feedingstuffs. Food Addit. Contam. Part A-Chem. 30,
- 453 1870-1887.
- 454 Boix, C., Ibáñez, M., Sancho, J.V., León, N., Yusá, V., Hernández, F. 2014. Qualitative
- 455 screening of 116 veterinary drugs in feed by liquid chromatography-high resolution
- 456 mass spectrometry: Potential application to quantitative analysis. Food Chem. 160,457 313-320.
- 458 Bransden, M.P., Carter, C.G., Nowak, B.F. 2001. Effects of dietary protein source on
- 459 growth, immune function, blood chemistry and disease resistance of Atlantic salmon

460 (Salmo salar L.) parr. Anim. Sci. 73,105-113.

- 461 Burr, G.S., Wolters, W.R., Barrows, F.T., Hardy, R.W. 2012. Replacing fishmeal with
- 462 blends of alternative proteins on growth performance of rainbow trout
- 463 (Oncorhynchus mykiss), and early or late stage juvenile Atlantic salmon (Salmo
- 464 salar). Aquaculture 334, 110-116.
- 465 Chapman, H.D. 2014. Milestones in avian coccidiosis research: A review. Poult. Sci.
 466 93, 501-511.
- 467 EC, 1996. Council Directive 96/23/EC of 29 April 1996 on measures to monitor
- 468 substances and residues thereof of in live animals and animal products and repealing
- 469 Directives 85/358/EEC and 86/469/EEC and Decisions 89/187/EEC and
- 470 91/664/EEC. Official Journal of the European Communities L125, 10.

471	EC, 2001. Regulation (EC) N° 999/2001 of the european parliament and of the council
472	of 22 May 2001 laying down rules for the prevention, control and eradication of
473	certain transmissible spongiform encephalopathies. Official Journal of the European
474	Union L 147, 1-38.
475	EC, 2002. Commission Decision (EC) Nº 2002/657 implementing Council Directive
476	96/23/EC concerning the performance of analytical methods and the interpretation of
477	results. Official Journal of the European Communities L221, 8-36.

478 EC, 2003a. Commission regulation 1234/2003 of 10 July 2003 amending Annexes I, IV

479 and XI to Regulation (EC) N° 999/2001 of the European Parliament and of the

480 Council and Regulation (EC) Nº 1326/2001 as regards transmissible spongiform

481 encephalopathies and animal feeding. Official Journal of the European Union L 173,
482 6-13.

483 EC, 2003b. Regulation (EC) N°1831/2003 of the European Parliament and of the

484 Council of 22 September 2003 on additives for use in animal nutrition Commission
485 directive 2009/8/EC.

486 EC, 2009a. Commission regulation (EU) No 37/2010 of 22 December 2009 on

487 pharmacologically active substances and their classification regarding maximum

488 residue limits in foodstuffs of animal origin. Official Journal of the European Union

489 L 15, 1-72.

490 EC, 2009b. Commission Directive 2009/8/EC of 10 February 2009 amending Annex I

491 to Directive 2002/32/EC of the European Parliament and of the Council as regards

492 maximum levels of unavoidable carry-over of coccidiostats or histomonostats in

493 nontarget feed. Official Journal of the European Union L 40, 19.

494 EC, 2009c. Regulation (EC) N° 1069/2009 of the European Parliament and of the

495 Council of 21 October 2009 laying down health rules as regards animal by-products

- 496 and derived products not intended for human consumption and repealing Regulation
- 497 (EC) Nº 1774/2002 (Animal by-products Regulation).
- 498 EC, 2013a. Commission regulation (EU) Nº 56/2013 of 16 January 2013 amending
- 499 Annexes I and IV to Regulation (EC) N° 999/2001 of the European Parliament and of
- 500 the Council laying down rules for the prevention, control and eradication of certain
- 501 transmissible spongiform encephalopathies. Official Journal of the European Union
- 502 21, 3-16.
- 503 EC, 2013b. SANCO/12571/2013. Guidance document on analytical quality control and
- validation procedures for pesticide residues analysis in food and feed.
- 505 EFSA, 2011. Scientific Opinion on the revision of the quantitative risk assessment
- 506 (QRA) of the BSE risk posed by processed animal proteins (PAPs). EFSA Panel on

507 Biological Hazards (BIOHAZ). EFSA Journal 9, 1947.

508 EMA, 2011. Trends in the sales of veterinary antimicrobial agents in nine European

509 countries Reporting period: 2005-2009. (EMA/238630/2011),

- 510 http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/2009/WC500
 511 112309.pdf.
- 512 FAO, 2014. The State of World Fisheries and Aquaculture 2014. FAO Fisheries and
- 513 Aquaculture Department Food and Agriculture Organization of the United Nations,
- 514 Rome (2014). http://www.fao.org/3/a-i3720e.pdf.
- 515 FDA 2015, FVM Executive Council 2015. Foods and Veterinary Medicine Science and
- 516 Research Steering Committee. Guidelines for the Validation of Chemical Methods
- 517 for the FDA FVM Program. 2nd Edition. US Food & Drug Administration, Office of
- 518 Food and Veterinary Medicine.
- 519 Friesen, E.N., Ikonomou, M.G., Higgs, D.A., Ang, K.P., Dubetz, C., 2008. Use of
- 520 terrestrial based lipids in aquaculture feeds and the effects on flesh organohalogen

- and fatty acid concentrations in farmed Atlantic salmon. Environ. Sci. Technol. 42,
 3519-3523.
- 523 Gillings, M.R., 2013. Evolutionary consequences of antibiotic use for the resistome,

524 mobilome, and microbial pangenome. Front. Microbiol. 4, 1-19.

- 525 Gracia-Lor, E., Sancho, J.V., Hernández, F. 2010. Simultaneous determination of
- 526 acidic, neutral and basic pharmaceuticals in urban wastewater by ultra high-pressure
- 527 liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1217, 622-632.
- 528 Grave, K., Hansen, M.K., Kruse, H., Bangen, M., Kristoffersen, A.B., 2008.
- 529 Prescription of antimicrobial drugs in Norwegian aquaculture with an emphasis on
- 530 "new" fish species. Prev. Vet. Med. 83, 156-169.
- 531 Hernández, F., Ibáñez, M., Botero-Coy, A.M., Bade, R., Bustos-López, M.C., Rincón,
- J., Moncayo, A., Bijlsma, L., 2015. LC-QTOF MS screening of more than 1,000 licit
- and illicit drugs and their metabolites in wastewater and surface waters from the area

of Bogotá, Colombia. Anal. Bioanal. Chem. 407, 6405-6416.

- 535 Ibáñez, M., Portolés, T., Rúbies, T., Muñoz, E., Muñoz, G., Pineda, L., Serrahima, E.,
- 536 Sancho, J.V., Centrich, F., Hernández, F., 2012. The power of hyphenated
- 537 chromatography/time-of-flight mass spectrometry in public health laboratories. J.
- 538 Agric. Food Chem. 60, 5311-5323.
- 539 Love, D.C., Halden, R.U., Davis, M.F., Nachman, K.E., 2012. Feather meal: A
- 540 previously unrecognized route for reentry into the food supply of multiple
- 541 pharmaceuticals and personal care products (PPCPs). Environ. Sci. Technol. 46,
- 542 3795-3802.
- 543 Mani, S., Bharagava, R.N., 2016. Exposure to Crystal Violet, Its Toxic, Genotoxic and
- 544 Carcinogenic Effects on Environment and Its Degradation and Detoxification for
- 545 Environmental Safety. Rev. Environ. Contam. T. 237, 71-104.

546	Masiá, A., Campo, J., Blasco, C., Picó, Y., 2014. Ultra-high performance liquid
547	chromatography-quadrupole time-of-flight mass spectrometry to identify
548	contaminants in water: An insight on environmental forensics. J. Chromatogr. A
549	1345, 86-97.
550	Nácher-Mestre, J., Ibáñez, M., Serrano, R., Pérez-Sánchez, J., Hernández, F., 2013.
551	Qualitative screening of undesirable compounds from feeds to fish by liquid
552	chromatography coupled to mass spectrometry. J. Agr. Food Chem. 61, 2077-2087.
553	Paterson, J.R., Baxter, G., Dreyer, J.S., Halket, J.M., Flynn, R., Lawrence, J.R., 2008.
554	Salicylic acid sans aspirin in animals and man: Persistence in fasting and
555	biosynthesis from benzoic acid. J. Agric. Food. Chem. 56, 11648-11652.
556	Poppi, D.A., Quinton, V.M., Hua, K., Bureau, D.P., 2011. Development of a test diet

558 (Oncorhynchus mykiss). Aquaculture 314, 100-109.

559 Rahnema, S., Borton, R., 2007. Determination of the effects of fish vs plant and feather

for assessing the bioavailability of arginine in feather meal fed to rainbow trout

560 meal-based diets on the growth and health of rainbow trout. J. Appl. Anim. Res. 32,

561 113-117.

557

562 Reig, M., Toldra. F. Veterinary Drugs and Growth Promoters Residues in Meat and

563 Processed Meats. Springer, 2009, 233 Spring Street, New York, Ny 10013, United564 States.

565 Rosenlund, G., Obach, A., Sandberg, M.G., Standal, H., Tveit, K., 2001. Effect of

alternative lipid sources on long-term growth performance and quality of Atlantic
salmon (Salmo salar L.). Aquac. Res. 32, 323-328.

Ruff, M.D., 1999. Important parasites in poultry production systems. Vet. Parasitol. 84,
337-347.

570	Scotter, M.J., Roberts, D.P.T., Wilson, L.A., Howard, F.A.C., Davis, J., Mansell, N.,
571	2007. Free salicylic acid and acetyl salicylic acid content of foods using gas
572	chromatography-mass spectrometry. Food Chem. 105, 273-279.
573	Serratosa, J., Blass, A., Rigau, B., Mongrell, B., Rigau, T., Tortades, M., Tolosa, E.,
574	Aguilar, C., Ribo, O., Balague, J., 2006. Residues from veterinary medicinal
575	products, growth promoters and performance enhancers in food-producing animals:
576	A European Union perspective. J. Rev. Sci. Tech. Off Int. Epizoot. 25, 637-653.
577	Tacon, A.G J., Metian, M., 2008. Global overview on the use of fish meal and fish oil in
578	industrially compounded aquafeeds: Trends and future prospects. Aquaculture 285,
579	146-158.

- 580 Toldra, F., Aristoy, M.C., Mora, L., Reig, M., 2012. Nutritional pork meat compounds 581 as affected by ham dry-curing. Meat Sci. 92, 290-296.
- 582 Torrissen, O., Olsen, R.E., Toresen, R., Hemre, G.I., Tacon, A.G.J., Asche, F., Hardy,
- 583 R.W., Lall, S., 2011. Atlantic Salmon (Salmo salar): The "Super-Chicken" of the
- 584 Sea?. Rev. Fish Sci. 19, 257-278.

- 585 Turnipseed, S.B., Lohne, J.J., Storey, J.M., Andersen, W.C., Young, S.L., Carr, J.R.,
- 586 Madson, M.R., 2014. Challenges in implementing a screening method for veterinary
- 587 drugs in milk using liquid chromatography quadrupole time-of-flight mass
- 588 spectrometry. J. Agr. Food Chem. 62, 3660-3674.
- 589 Venema, D.P., Hollman, P.C.H., Janssen, K.P.L.T.M., Katan, M.B., 1996.
- 590 Determination of acetylsalicylic acid and salicylic acid in foods, using HPLC with
- 591 fluorescence detection. J. Agric. Food Chem. 44, 1762-1767.
- 592 Waagbo, R., Berntssen, M.H.G., Danielsen, T., Helberg, H., Kleppa, A.L., Lea, T.B.,
- 593 Rosenlund, G., Tvenning, L., Susort, S., Vikesa, V., Breck, O., 2013. Feeding
- 594 Atlantic salmon diets with plant ingredients during the seawater phase - a full-scale

595	net p	roduction c	of marine	protein	with	focus or	n biol	ogical	performance.	welfare.
- / -	P			P-0.0				- 8	p,	

- 596 product quality and safety. Aquac. Nutr. 19, 598-618.
- 597 WADA World Anti-Doping Agency. International Standard for Laboratories.

598 Identification criteria for qualitative assays TD2010IDCR.

- 599 Wilson, C.M., Friesen, E.N., Higgs, D.A., Farrell, A.P., 2007. The effect of dietary lipid
- and protein source on the swimming performance, recovery ability and oxygen
- 601 consumption of Atlantic salmon (*Salmo salar*). Aquaculture 273, 687-699.
- 602 Yanik, T., Dabrowski, K., Bai, S.C., 2003. Replacing fish meal in rainbow trout
- 603 (Oncorhynchus mykiss) diets. Isr. J. Aquac-Bamidgeh 55, 179-186.

618

619	Figure 1. Scheme of detection and identification criteria for HRMS screening used in
620	this work.

- 621 Figure 2. nw-XICs for enrofloxacin in: (A) standard in solvent at 250 ng/mL; (B)
- 622 quality control of poultry meal A at 0.1 mg/kg; (C) poultry meal C sample. In each case,
- 623 chromatograms for the LE function (bottom) and HE (top) are shown to illustrate the
- 624 presence of the protonated molecule (LE) and fragment ions (HE). ✓ Accurate mass
- 625 deviations within tolerance limits (below 5 ppm). \checkmark q/Q ratio tolerance accepted by
- 626 Com. Decision 2002/657/EC.
- 627 **Figure 3**. nw-XICs illustrating the identification of: (A) trimethoprim in feather meal;
- 628 (B) flumequine in feather meal; (C) salicylic acid in pork blood meal. ✓ Accurate mass
- 629 deviations within tolerance limits (below 5 ppm). \checkmark q_i/Q ratio tolerance accepted by
- 630 Com. Decision 2002/657/EC.
- 631 Figure 4. nw-XICs illustrating the detection of: (A) leucocrystal violet in poultry blood
- 632 meal A; (B) tylosin A in poultry blood meal. ✓/× Accurate mass deviations
- 633 within/without tolerance limits. $\checkmark/\varkappa q_i/Q$ ratio tolerance accepted/not permitted by
- 634 Com. Decision 2002/657/EC.
- 635

Pharmaceuticals & Dyes	Poultry blood meal A	Poultry blood meal B	Poultry blood meal C	Poultry blood meal D	Poultry meal A	Poultry meal B	Poultry meal C	Poultry meal D	Feather meal A	Feather meal B	Feather meal C	Pork blood meal A	Pork blood meal B	Pork blood meal C	Pork meal A	Pork meal B	Pork meal C	Pork greaves A	Pork greaves B
Acetaminophen	-	-	-	-	-	d1	-	d1	-	-	-	-	-	-	-	-	-	d 1	-
Enrofloxacin	-	-	-	-	-	-	\checkmark	-	-	-	-	-	-	-	-	-	-	-	-
Flumequine	-	-	-	-	-	-	-	-	\checkmark	-	-	-	-	-	-	-	-	-	-
Leucocrystal violet	d2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Monensin	-	-	-	-	-	-	d1	-	-	-	-	-	-	-	-	-	-	-	-
Oxyphenylbutazone	-	d1	-	-	-	-	-	-	-	-	-	-	-	d 1	-	-	-	-	-
Salicylic acid	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	d1	d1	d1	d 1	d1
Trimethoprim	-	-	-	-	-	-	-	-	\checkmark	-	-	-	-	-	-	-	-	-	-
Tylosin A	-	-	-	d2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

637 Table 1. Compounds detected and identified from the LC-HRMS screening.

638 d: detected (d1 and d2 are defined in Figure 1); \checkmark : identified.



Figure 1.







Figure 3.



